Table 1.
Patient demographics
| No. of patients | |
|---|---|
| Total no. of patients | 9 |
| Sex | |
| Male | 5 |
| Female | 4 |
| Primary site | |
| Cutaneous | 7 |
| Acral | 1 |
| Ocular | 1 |
| Prior therapy | |
| Surgery | 9 |
| Isolated limb perfusion | 1 |
| Radiation | 4 |
| Adjuvant interferon | 4 |
| Temozolomide | 3 |
| BRAF inhibitor | 2 |
| BRAF inhibitor + MEK inhibitor | 2 |
| Ipilimumab | 1 |
| hu14.18-IL2 | 1 |
| Sites of metastatic disease | |
| Regional metastases alone | 1 |
| Distant node, skin, subcutaneous | 6 |
| Lung | 7 |
| Other visceral metastasesa | 3 |
| Disease status | |
| III, recurrent | 1 |
| M1ab | 1 |
| M1bc | 4 |
| M1 cd | 3 |
| Performance Statuse | |
| 0 | 6 |
| 1 | 3 |
Median age, 63 years; range 42–77 years
aAdrenal, bone, liver, pleura
bMetastatic disease to distant nodes, skin, or subcutaneous lesions
cMetastatic disease to lung
dMetastatic disease to other visceral sites or M1a, M1b disease with elevated lactate dehydrogenase
eEastern Cooperative Oncology Group Performance Status